Expression of insulin-like growth factor Ⅱ and its receptor in liver cells of chronic liver diseases

AIM To clarify the relationship between the Insulin like growth factor Ⅱ (IGF Ⅱ), IGF Ⅱ receptor and chronic liver diseases and to provide evidences for basic and clinical researches for exploring the potential mechanisms of human hepatocellular carcinoma (HCC). METHODS The poly (A)+ mRNA translation of IGF Ⅱ and IGF Ⅱ receptor in dysplasia liver cell (DLC n =10), liver cirrhosis (LC n =9) and chronic active hepatitis (CAH n =9) were analyzed with RNA gel electrophoresis, Northern blot and hybridization using human IGF Ⅱ and IGF Ⅱ receptor DNA probes labelled with 32 P through Nick translation and autoradiography. RESULTS The overexpression of IGF Ⅱ in DLC (10/10, 100%) was apparently higher than that in CAH (3/9, 33%) and LC (3/9, 33%), ( P <0 01). The overexpression of IGF Ⅱ receptor in DLC (7/10, 70%) was significantly higher than that in CAH (2/9, 22%) and LC (3/9, 33%), respectively. The data of HBV infection from different chronic liver diseases were analyzed. CONCLUSION The overexpression of IGF Ⅱ and IGF Ⅱ receptor in DLC was related to the preceeding of malignant phenotype of hepatocyte, which provided a diagnostic value for early detection of hepatocellular carcinoma (HCC). Persistent HBV infection is strongly associated with abnormal activation of IGF Ⅱ and IGF Ⅱ receptor, which might indicate a stimulating mechanism of autocrine or paracrine growth involved in live cell carcinogenesis.

Reactivation of the insulin-like growth factor-Ⅱsignaling pathway in human hepatocellular carcinoma

Constitutive activation of the insulin-like growth factor (IGF)-signaling axis is frequently observed in human hepatocellular carcinoma(HCC).Especially the over- expression of the fetal growth factor IGF-Ⅱ,IGF-Ⅰ receptor(IGF-IR),and cytoplasmic downstream effectors such as insulin-receptor substrates(IRS)contribute to proliferation,anti-apoptosis,and invasive behavior. This review focuses on the relevant alterations in this signaling pathway and independent in vivo models that support the central role IGF-Ⅱsignaling during HCC development and progression.Since this pathway has become the center of interest as a target for potential anti-cancer therapy in many types of malignancies,various experimental strategies have been developed,including neutralizing antibodies and selective receptor kinase inhibitors,with respect to the specific and efficient reduction of oncogenic IGF-Ⅱ/IGF-IR-signaling.

Interplay between micro RNA-17-5p, insulin-like growth factor-Ⅱ through binding protein-3 in hepatocellular carcinoma

AIM: To investigate the effect of microR NA on insulinlike growth factor binding protein-3(IGFBP-3) and hence on insulin-like growth factor-Ⅱ(IGF-Ⅱ) bioavailability in hepatocellular carcinoma(HCC).METHODS: Bioinformatic analysis was performed using microrna.org, DIANA lab and Segal lab softwares. Total RNA was extracted from 23 HCC and 10 healthy liver tissues using mir Vana mi RNA Isolation Kit. microR NA-17-5p(miR-17-5p) expression was mimicked and antagonized in Hu H-7 cell lines using Hi Per Fect Transfection Reagent, then total RNA was extracted using Biozol reagent then reverse transcribed into cD NA followed by quantification of mi R-17-5p and IGFBP-3 expression using Taq Man real-time quantitative PCR. Luciferase reporter assay was performed to validate the binding of miR-17-5p to the 3'UTR of IGFBP-3. Free IGF-Ⅱ protein was measured in transfected Hu H-7 cells using IGF-Ⅱ ELISA kit. RESULTS: Bioinformatic analysis revealed IGFBP-3 as a potential target for miR-17-5p. Screening of miR-17-5p and IGFBP-3 revealed a moderate negative correlation in HCC patients, where mi R-17-5p was extensively underexpressed in HCC tissues(P = 0.0012), while IGFBP-3 showed significant upregulation in the same set of patients(P = 0.0041) compared to healthy donors. Forcing mi R-17-5p expression in Hu H-7 cell lines showed a significant downregulation of IGFBP-3 mR NA expression(P = 0.0267) and a significant increase in free IGF-Ⅱ protein(P = 0.0339) compared to mock untransfected cells using unpaired t-test. Luciferase assay validated IGFBP-3 as a direct target of mi R-17-5p; luciferase activity was inhibited by 27.5% in cells co-transfected with miR-17-5p mimics and the construct harboring the wild-type binding region 2 of IGFBP-3 compared to cells transfected with this construct alone(P = 0.0474).CONCLUSION: These data suggest that regulating IGF-Ⅱ bioavailability and hence HCC progression can be achieved through targeting IGFBP-3 via manipulating the expression of miR NAs.

Expression of insulin-like growth factor Ⅱ and its receptor in hepatocellular carcinogenesis

INTRODUCTIONInsulin-like growth factor Ⅱ(IGF-Ⅱ) is a mitogenic peptide of 74 kD and is mostly synthesized in fetal liver tissue .IGF-Ⅱ is believed to play an important role in fetal growth and development and is involved in cellular proliferation and differentiation[1-5]. Recently ,several researchers have reported increased expression of the IGF-Ⅱgene in human hepatocellular carcinoma (HCC) and adjacent non-cancerous liver tissues [6-10].

The immunocytochemical localization of insulin-like growth factor Ⅱ in human cirrhosis

Sections of 30 cases of human cirrhosis were stained with rabbit anti-insulin-likegrowth factor Ⅱ(IGF Ⅱ)by double PAP method.By the serological examination 15 patientsshowed HBV infection and sections of 14 eases were HBsAg postively with a total rate of 67％(20 cases).The IGF Ⅱ was positive in the cytoplasm of all the liver and ductular cells.Binucle-ated,polypoid liver cells and the peripheral cells of the lobules or nodules were distinctly posi-tive,The liver cells which were strongly positive were a kind of thin polygonal cells with asmall oval or a round deeply stained nucleus in each.They might exist sporadically in the lob-ules or in the marginal portion of a nodule.These liver cells are quite different from the so-called oval cells which are derived from the proliferating ductules and are generally believed tobe responsible for the pathogensis of hepatoma.

Changes of insulin-like growth factor-Ⅱ and insulin-like growth factor binding protein-3 in cerebrospinal fluid of children with tuberculous meningitis

BACKGROUND： Recent studies have found that insulin-like growth factors （IGFs） and insulin-like growth factor binding protein-3 （IGFBP-3） have stronger neurotrophic and neuroprotective effects. But whether their levels in cerebrospinal fluid could be used as an auxiliary indicator in differentially diagnosing tuberculous meningitis and viral encephalitis is not yet clear. OBJECTIVE： To explore the changes of insulin-like growth factor-Ⅱ （IGF-Ⅱ ） and IGFBP-3 in cerebrospinal fluid （CSF） of children with tuberculous meningitis and the significance of the changes. DESIGN： A non-randomized concurrent controlled study. SETTING： Department of Pediatric Internal Medicine, the First Affiliated Hospital of Xinxiang Medical College. PARTICIPANTS： Thirty children with tuberculous meningitis （14 males and 16 females） were selected from the Department of Pediatric Internal Medicine, the First Affiliated Hospital of Xinxiang Medical College from January 2005 to December 2006. Tuberculous meningitis was diagnosed according to their clinical manifestations, the history of close contact with tuberculosis, typical cerebrospinal fluid changes of tuberculous meningitis, positive tuberculosis antibody and effective antituberculosis treatment. There were 30 children （13 males and 17 females） with viral encephalitis, and viral encephalitis was diagnosed according to epidemiological history, clinical manifestations, conventional and biochemical changes of cerebrospinal fluid, and negative bacteriology judgment. Meanwhile, 30 children （13 males and 17 females） without infectious and central nervous system disease were selected as the control group. Informed consent was obtained from the parents of all the enrolled children. METHODS： ①The lumbar puncture operation was implemented immediately to obtain cerebrospinal fluid （3 mL）. The contents of IGF-Ⅱ and IGFBP-3 were detected with immunoradiometric assay. The concentrations of glucose and protein in cerebrospinal fluid were determined with a dry-chemical method. The number of white blood cells was counted by Fushi Method. ②The Pearson correlation analysis was used to analyze the correlation of the contents of IGF-Ⅱ and IGFBP-3 in cerebrospinal fluid with the leucocyte counting and the concentrations of glucose and protein in cerebrospinal fluid. MAIN OUTCOME MEASURES： The contents of IGF- Ⅱ and IGFBP-3 in cerebrospinal fluid, and their correlation with the leucocyte counting and the concentrations of glucose and protein in cerebrospinal fluid. RESULTS： ①Contents of IGF-Ⅱ and IGFBP-3 in cerebrospinal fluid： The contents of IGF-Ⅱ and IGFBP-3 in cerebrospinal fluid in the tuberculous meningitis group were significantly higher than those in the encephalitis virus group and control group （P 〈 0.05）. There was no significant difference in the contents of IGF- Ⅱ and IGFBP-3 in cerebrospinal fluid between the viral encephalitis group and control group （P 〉 0.05）. ②Correlation： The IGF- Ⅱ and IGFBP-3 contents in cerebrospinal fluid were positively correlated with the protein concentration in cerebrospinal fluid （r =0.821, 0.855, P 〈 0.01）, but negatively with the glucose （r =0.742, - 0.605, P 〈 0.01）. CONCLUSION- ①IGFs and IGVBPs are involved in the pathophysiological process of tuberculous meningitis, as well as the glucose and protein metabolism in cerebrospinal fluid. ②The IGF-Ⅱ and IGFBP-3 contents in cerebrospinal fluid can be used as the auxiliary indicators to differentially diagnose tuberculous meningitis and viral enceohalitis.

Antisense oligonucleotide to insulin-like growth factorⅡ induces apoptosis in human ovarian cancer AO cellline

The effects of antisense oligonucleotide to insulin-like growth factor 11 (IGFII) to induce apoptosis in human ovarian cancer cells were evaluated. Antiproliferation effects of antisense to IGFII in ovarian cancer AO cells were determined by 3H-thymidine incorporation. Apoptosis of the IGFll antisense-treated cells was quantitated by both nuclear condensation and flow cytometry after cells were stained with propidium iodide. IGFII antisense (4.5μM)treatment of 48 h maximally inhibited proliferation of AO cells. More than 25% of IGFII antisense-treated cells (4.5PM for 24 h) had undergone apoptosis, whereas less than 3% of the cells were apoptotic in either IGFII sense-treatedcells or untreated cells. Antisense oligonucleotide to IGFII significantly inhibited cell proliferation and induced apoptosis in human ovarian cancer AO cell. These data suggest that IGFII may be a potential target in treatment of ovarian cancer and antisense oligonucleotide to IGFⅡmay serve as a therapeutic approach.

母乳IGF-Ⅱ与婴儿体格生长指标关联性分析及影响因素研究

目的描述哺乳期各阶段母乳IGF-Ⅱ浓度的变化,探讨哺乳期不同阶段母乳IGF-Ⅱ与婴儿体格生长指标的关联,以及可能影响母乳IGF-Ⅱ浓度的因素。方法2020年10月至2021年9月于北京大学人民医院招募32名满足纳入排除标准的分娩妇女,分别于分娩后48 h、产后15 h、产后42 h、6个月、9个月及12个月采集妇女母乳标本,同时收集婴儿身长、体重等生长发育指标。采用酶联免疫吸附方法检测母乳IGF-Ⅱ水平。使用广义估计方程(GEE)分析母乳IGF-Ⅱ水平与婴儿体格生长指标之间的关联以及可能影响母乳IGF-Ⅱ水平的因素。结果母乳IGF-Ⅱ中位浓度在12月成熟乳中最高(82.5 ng/mL),6月成熟乳中最低(55.3 ng/mL),呈先下降再升高趋势,但各阶段中位浓度间未见明显差异;在调整母亲年龄、孕前BMI、孕周、母亲民族、孕产史、孕期并发症情况(妊娠期糖尿病、妊娠期高血压、妊娠期甲状腺疾病)、婴儿喂养方式及婴儿性别后,研究结果显示初乳中IGF-Ⅱ含量与婴儿身长呈正相关关系(β=0.9,P<0.01),初乳、42d成熟乳、12月成熟乳中的IGF-Ⅱ含量与婴儿体重呈正相关关系(P=0.02,P<0.01和P=0.01)。将膳食炎症指数(DII)按三分位法分为三组(Q1:最抗炎倾向组,Q2:中间组,Q3:最促炎倾向组)纳入GEE模型,结果显示,第三分位组(即最促炎倾向组)与母乳IGF-Ⅱ含量正相关(β=28.6,P=0.01)。结论母乳IGF-Ⅱ对婴儿身长、体重存在一定的促进作用,孕期促炎饮食与母乳IGF-Ⅱ含量相关。

Effects of Tanshinone ⅡA on Transforming Growth Factor β1-Smads Signal Pathway in Renal Interstitial Fibroblasts of Rats

The effects of tanshinone ⅡA （TSN） on transforming growth factor β1 （TGFβ1） signal transduction in renal interstitial fibroblasts of rats were studied in order to investigate its mechanism in prevention of renal interstitial fibrosis. Rat renal fibroblasts of the line NRK/49F were cultured in vitro, stimulated with 5 ng/mL TGFβ1 and pretreated with 10-6, 10-5, 10-4 mol/L TSN respectively. The mRNA levels of fibronectin （FN） were examined by RT-PCR. The protein expression of FN and Smads was detected by Western blot. TGFβ1 induced the expression of FN mRNA and Smads in a time-dependent manner in a certain range. Compared with pre-stimulation, the FN mRNA and protein levels were increased by 1.1 times and 1.5 times respectively （P〈0.01, P〈0.01）, and the protein expression of phosphorylated Smad2/3 （p-Smad2/3） increased by 7 times at the end of TGFβ1 stimulation （P〈0.01）. TSN pretreatment may down-regulate the FN and p-Smad2/3 expression in a dose-dependent manner. 10-6 mol/L TSN pretreatment had no effect on the FN and p-Smad2/3 expression （both P〉0.05）. After pretreatment with 10-5 and 10-4 mol/L TSN, the FN mRNA levels were decreased by 28.1% and 43.8% respectively （P〈0.05, P〈0.01）, the FN protein levels were decreased by 40% and 44% respectively （P〈0.05, P〈0.05）, and the p-Smad2/3 protein expression were decreased by 40% and 65% respectively （P〈0.05, P〈0.01）. The inhibitory effect of TSN on renal interstitial fibrosis may be related to its blocking effect on TGFβ1-Smads signal pathway in renal intersti- tial fibroblasts.

Detection of Frameshift Mutations of the Transforming Growth Factor p ReceptorⅡin Gastric Cancers with Microsatellite Instability

OBJECTIVE To study the relationship among microsatellite instability （MSI）, frameshift mutations （FM） of the transforming growth factor β receptor Ⅱ （TGF β R Ⅱ）, methylation state of the hMLH1 promoter and hMLH1 protein expression level in gastric cancers, and to explore their relationship to gastric carcinogenesis. METHODS DNA was isolated from 101 gastric specimens and 5 microsatellite loci were detected. PCR, electrophoresis on denatured polyacrylamide gels and silver staining were performed to detect the MSI. The FMs of TGFβR Ⅱ were also screened with the same method. HMLH1 methylation was analyzed by methylation specific PCR （MSP） and sequencing. HMLH1 protein expression was detected using immunohistochemistry. RESULTS The incidence of MSIs was 53.7% and 0% in the cancers and normal tissues, respectively, with the frequency of MSIs being significantly higher in the gastric cancers compared to the normal gastric tissues （P〈0.05）. The frequency of hMLH1 methylation was 41.5%（17/41） in the gastric cancers and 0%（0/60） in the normal group. Decreased hMLH1 expression was observed in 94.1%（16/17） of cases exhibiting methylation. FMs of TGFβR Ⅱ were identified in 5 （62.5%） of the 8 samples with MSIH. In contrast, FMs were not found in MSI-L or microsatellite stable （MSS） cases. CONCLUSION MSIs and FMs of TGFβR Ⅱ may play an important role in gastric carcinogenesis. HMLH1 methylation is an important modification of the DNA which results in inactivation of hMLH1 and mismatch repair defects which lead to MSls and FMs of TGFβR Ⅱ.

Transforming growth factor β receptor Ⅱ expression inexperimental cryptorchidism and apoptosisin spermatogenic cells in rats

Objective: To study the transforming growth factor β receptor Ⅱ (TGFβ-R Ⅱ) expression in experimental cryptorchidism and apoptosis in spermatogenic cells in rats. Methods: The apoptosis of spermatogenic cells was detected by means of the terminal deoxynucleotldyl transferase mediated dUTP nick end lableling method (TUNEL) and the TGFβ-R Ⅱ expression was observed with the immunohistochemistry SABC methods. Results: There was a significant increase in the TGFβ-R Ⅱ expression in unilateral undescended testes (UUTs) compared with that in contralateral descended testes (CDTs, P<0.01). However, there was a significant and time-dependent increase in the mean apoptotic index in UUTs than in CDTs. Conclusion: TGFβ-R Ⅱ may play an important role in spermatogenic cell apoptosis.

IGF-Ⅱ对肝癌细胞MHCC97-H癌基因C-myc和N-ras表达的影响

目的观察胰岛素样生长因子Ⅱ(IGF-Ⅱ)对肝癌细胞MHCC97-H中癌基因C-myc和N-ras表达的影响。方法培养肝癌细胞株MHCC97-H,用IGF-Ⅱ(50ng/mL)作用48h后,分别采用细胞免疫荧光、Western blot法及Real-time PCR法检测细胞中C-myc和N-ras的表达情况,并与对照组比较,进行定量分析。结果 C-myc及N-ras蛋白阳性表达主要位于细胞核。对照组、IGF-Ⅱ组MHCC97-H细胞中C-myc荧光表达量分别为(100.00±2.89)%、(254.00±35.57)%,N-ras荧光表达量分别为(100.00±14.43)%、(257.30±22.43)%。与对照组相比,IGF-Ⅱ组MHCC97-H细胞中C-myc及N-ras蛋白表达明显增强,差异有统计学意义(P<0.05)。与对照组相比,IGF-Ⅱ组MHCC97-H细胞中C-myc和N-ras的mRNA表达明显增加,差异有统计学意义(P<0.05)。结论 IGF-Ⅱ可上调肝癌细胞MHCC97-H中癌基因C-myc和N-ras的蛋白及mRNA表达,这可能是IGF-Ⅱ促进肝癌细胞增殖的分子机制之一,这为临床上肝癌防治提供了新线索。

IGF-Ⅱ和IGF-Ⅰ R在大肠癌中的表达

目的研究胰岛素样生长因子-(IGF-)和胰岛素样生长因子受体(IGF-R)在国人大肠癌中的表达情况及其与临床病理的关系。方法应用免疫组织化学过氧化物酶标记链霉卵白素法(S-P)对40例大肠癌患者的大肠癌组织、距大肠癌原发灶1cm癌旁组织、距大肠癌原发灶10cm以上大肠组织和10例非肿瘤患者的正常大肠组织标本,进行IGF-和IGF-R的抗原染色。结果1大肠癌组织和癌旁组织中IGF-和IGF-R的表达率显著高于切缘组织和正常大肠组织的表达率(P<0.05)。癌组织和癌旁组织中IGF-和IGF-R的表达率无显著性差异(P>0.05)。切缘组织和正常大肠组织中IGF-和IGF-R的表达率无显著性差异(P>0.05)。2在有淋巴结转移和Dukes分期C期及浸透全层组中IGF-和IGF-R的表达率分别显著高于无淋巴结转移组和Dukes分期A、B期及未浸透全层组中GF-和GF-R的表达率(P<0.05)。结论IGF-、IGF-R的高表达与大肠癌的发生发展和侵袭转移密切相关。

IGF-Ⅰ和IGF-Ⅱ在人结直肠腺瘤和结直肠癌中的表达及意义

目的探讨IGF-Ⅰ和IGF-Ⅱ与结直肠腺瘤及结直肠癌发生、发展的关系。方法用免疫组化法检测IGF-Ⅰ和IGF-Ⅱ在人结直肠腺瘤和结直肠癌中的表达,用IPWIN60软件测量染色情况,计算平均光密度。结果 IGF-Ⅰ、IGF-Ⅱ在正常肠粘膜中少量表达,在结直肠管状腺瘤和绒毛状腺瘤中表达明显增强,结直肠癌中则高表达。与正常肠粘膜组比较,结直肠管状腺瘤组、绒毛状腺瘤组、结直肠癌组的表达均有显著差异(P<0.01);与结直肠管状腺瘤组和绒毛状腺瘤组比较,IGF-Ⅰ和IGF-Ⅱ在结直肠癌中的表达显著增强(P<0.01)。结论 IGF-Ⅰ和IGF-Ⅱ在正常结直肠粘膜、管状腺瘤、绒毛状腺瘤、结直肠癌中的表达依次增加,IGF-Ⅰ和IGF-Ⅱ可能在结直肠腺瘤及结直肠癌的发生、发展中起一定作用。

肺癌患者化疗前后血清NSE、IGF-Ⅱ和TNF-α检测的临床意义

目的:探讨肺癌患者化疗前后血清NSE、IGF-Ⅱ和TNF-α含量的变化。方法:应用放射免疫分析检测38例肺癌患者化疗前后血清NSE、IGF-Ⅱ和TNF-α含量,并与35名正常健康人作比较。结果:肺癌患者在化疗前血清中NSE、IGF-Ⅱ和TNF-α水平均非常显著地高于正常人组(P<0.01),化疗后6个月在未复发的25例中明显下降接近于正常人组,而复发的5例,其数值又回升至化疗前水平(P<0.05)。结论:检测肺癌患者血清NSE、IGF-Ⅱ和TNF-α含量的变化可作为诊断和疗效观察的参考。

食管癌患者手术治疗前后血清Hcy、IGF-Ⅱ和TSGF检测的临床意义

目的:探讨了食管癌患者手术治疗前后血清Hcy、IGF-Ⅱ和TSGF水平的变化及意义。方法:应用免疫法和放射免疫分析对33例食管癌患者进行了手术治疗前后血清Hcy、IGF-Ⅱ和TSGF检测,并与35名正常人作比较。结果:食管癌患者在手术前血清Hcy、IGF-Ⅱ和TSGF水平非常显著地高于正常人组(P<0.01)手术后6个月未复发的29例中明显下降接近于正常人组,而复发的4例,其数值又回升至手术前水平(P<0.05)。结论:检测食管癌患者血清Hcy、IGF-Ⅱ和TSGF水平的变化可作为诊断和疗效观察的参考。

高脂血症患者AngⅡ和NO与IGF-1关系研究及通心络疗效

目的研究临床高胆固醇血症患者血管紧张素Ⅱ(AngⅡ)和一氧化氮(NO)与胰岛素样生长因子(IGF-1)相关性,探讨通心络干预疗效。方法观察入选的40名高胆固醇血症患者(TC>5.72mmol·L-1或LDL-C>3.64mmol·L-1)和35名健康体检者血管内皮依赖性舒张功能,并检测血清中AngⅡ、NO、IGF-1和可溶性E-选择素含量的变化,对高胆固醇血症患者AngⅡ与IGF-1以及NO与IGF-1进行pearson相关分析,并将40例高胆固醇血症患者,随机双盲分成两组,通心络组:20例,在常规饮食控制基础上,予通心络胶囊每次4粒(每粒为0.26g),每日3次,安慰剂组:20例,在常规饮食控制基础上服用安慰剂,疗程为8wk,观察通心络对上述指标以及血脂的影响。结果与健康体检者相比,高胆固醇血症患者血清NO和IGF-1含量明显降低,血管内皮依赖性舒张功能下降,而AngⅡ、可溶性E-选择素含量明显增高。高胆固醇血症患者AngⅡ与IGF-1呈负相关(r=-0.406,P<0.01),NO与IGF-1呈正相关(r=0.718,P<0.001)。使用通心络治疗8wk后,IGF-1、NO明显增加,血管内皮依赖性舒张功能明显改善,AngⅡ和可溶性E-选择素降低。结论IGF-1含量降低可能是高胆固醇血症患者血管内皮功能障碍的一个重要机制,通心络提高IGF-1水平可能是其对高胆固醇血症患者血管内皮保护的新机制。

肺癌患者化疗前后血清Hcy、IGF-Ⅱ和TSGF检测的临床意义

目的:探讨肺癌患者化疗前后血清Hcy、IGF-Ⅱ和TSGF水平的变化及临床意义。方法:应用免疫法和放射免疫分析对35例肺癌患者进行了血清Hcy、IGF-Ⅱ和TSGF含量检测,并与30名正常健康人作比较。结果:肺癌患者在化疗前血清Hcy、IGF-Ⅱ和TSGF水平均非常显著地高于正常人组(P<0.01),化疗后6个月在未复发的27例中明显下降接近于正常人组,而复发的8例,其数值又回升至化疗前水平(P<0.05)。结论:检测肺癌患者血清Hcy、IGF-Ⅱ和TSGF水平的变化可作为诊断和疗效观察的参考。

IGF-Ⅱ在早期胚胎发育终止蜕膜组织中的表达

目的 研究胰岛素样生长因子 Ⅱ (IGF Ⅱ )在早期胚胎发育终止中的表达以及母体血中IGF Ⅱ水平的改变与胚胎发育终止的关系。方法 采用免疫组织化学SP法检测早期胚胎发育终止蜕膜中IGF Ⅱ蛋白的表达 ;采用原位杂交法检测早期胚胎发育终止蜕膜中IGF ⅡmRNA的表达 ;采用酶联免疫吸附试验 (ELISA)检测正常妊娠及早期胚胎发育终止孕妇血中IGF Ⅱ水平的变化。结果 正常妊娠的蜕膜组织中IGF Ⅱ的表达明显高于胚胎发育终止组 (P<0 .0 1) ;正常妊娠组蜕膜中IGF ⅡmRNA的表达明显高于胚胎发育终止组 (P <0 .0 1) ;正常妊娠组母血中IGF Ⅱ水平也明显高于胚胎发育终止组 (P <0 .0 1)。结论 IGF Ⅱ在蜕膜组织中的表达水平与胚胎发育密切相关 ,其含量的减少可能是导致胚胎死亡的原因之一。

子宫颈癌患者血清IGF-Ⅱ、IL-8和Hcy检测的临床意义

目的:探讨子宫颈癌患者手术治疗前后血清IGF-Ⅱ、IL-8和Hcy检测的临床意义。方法:应用放射免疫分析和免疫化学法对33例子宫颈癌患者进行了手术治疗前后血清IGF-Ⅱ、IL-8和Hcy检测,并与35名正常健康人作比较。结果:子宫颈癌患者在手术治疗前血清IGF-Ⅱ、IL-8和Hcy水平均非常显著地高于正常人组(P<0.01)。手术治疗3个月后则与正常人组比较无显著性差异(P>0.05)。血清IGF-Ⅱ水平与IL-8和Hcy呈显著正相关(r=0.5786、0.6084,P<0.01)。结论:检测子宫颈癌患者手术治疗前后血清IGF-Ⅱ、IL-8和Hcy水平的变化对了解病情、观察疗效和预后判断均具有重要的临床价值。